Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

Tyrosine Kinase Inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with EGFR-TKI, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining PLB1004 with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer. In recent years, clinical studies on the combination of EGFR-T

Trial Details

NCT ID
NCT07063329
Phase
PHASE1 / PHASE2
Sponsor
Avistone Pharmaceutical(Ningbo)Co., LTD.
Status
RECRUITING
Cancer Type
Squamous Cell Lung Cancer
Interventions
  • PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy
  • RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\. Phase Ib Dose-escalation Part : Patients with histologically or cytologically confirmed unresectable locally advanced (stage IIIB and IIIC) or …
  • Patients with EGFR sensitive mutations: They must have received EGFR-TKI treatment. If only first/second-generation EGFR-TKIs were used, T790M nega…
  • Patients with other EGFR mutations such as EGFR exon 20 insertion: They must have received platinum-based chemotherapy.
  • Phase Ib Dose-expansion part and Cohort 1 of Phase II: Patients with histologically or cytologically confirmed unresectable locally advanced (stage…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Lung Cancer Trials on Trialify →